Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LMB-100 + Nab-paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LMB-100||RG7787||LMB-100 is an immunotoxin that targets mesothelin, potentially resulting in antitumor activity (PMID: 27863199).|
|Nab-paclitaxel||Abraxane||ABI-007|Paclitaxel Protein-bound||Chemotherapy - Taxane 2||Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic ductal adenocarcinoma||not applicable||LMB-100 + Nab-paclitaxel||Phase Ib/II||Actionable||In a Phase I/II trial, the combination of LMB-100 and Abraxane (nab-paclitaxel) led to a greater than 50% decrease in CA19-9 in 41% (7/17) of patients with pancreatic ductal adenocarcinoma, and one patient experienced an objective partial response, however, the combination therapy was not well tolerated (PMID: 31792036; NCT02810418).||31792036|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02798536||Phase I||LMB-100 LMB-100 + Nab-paclitaxel||Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma||Active, not recruiting|
|NCT02810418||Phase Ib/II||LMB-100 LMB-100 + Nab-paclitaxel||Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors||Active, not recruiting|